Biohaven Ltd.(BHVN)

$14.64—

Chart

Biohaven Ltd.(BHVN)

NYSE

$14.64—

Chart Studio

BHVN(BHVN)

BHVN

Overview Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.72

Nov 9, 2026

Revenue Estimate

$735,575

FY2030E EPS$0.34

Analyst Sentiment

Wall St. Consensus

Buy

24 analysts·High coverage

Score

17 Buy (71%)6 Hold (25%)1 Sell (4%)

Rating Breakdown

Strong Buy

00%

Buy

1771%

Hold

625%

Sell

14%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$10.00

-31.7%

Consensus

$13.00

-11.2%

Bull

$19.00

+29.8%

12-Month Target Range24 analysts

$10.00$13.00$19.00

Current $14.64Consensus

Current Price

$14.64

Above Consensus

$1.64

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+842.20%

EPS—

FY2028

Rev+360.08%

EPS—

FY2029

Rev+230.23%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$2M	$23M	$106M	$351M	$800M
Low	$2M	$17M	$106M	$298M	$679M
High	$3M	$29M	$107M	$404M	$921M
EBITDA Avg	—	—	—	—	—
Low	—	—	—	—	—
High	—	—	—	—	—
EBIT Avg	—	—	—	—	—
Low	—	—	—	—	—
High	—	—	—	—	—
Net Income Avg	$-310M	$-249M	$-295M	$-154M	$37M
Low	$-346M	$-329M	$-334M	$-184M	$30M
High	$-275M	$-168M	$-45M	$-123M	$44M
EPS Avg	$-2.99	$-2.37	$-1.95	$-1.43	$0.34
Low	$-3.21	$-3.06	$-3.10	$-1.71	$0.27
High	$-2.56	$-1.56	$-0.42	$-1.15	$0.41
Analysts (Rev / EPS)	8 / 9	10 / 10	15 / 14	10 / 7	7 / 11

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028	Q2 2028
Revenue Avg	$735,575	$980,075	$1M	$1M	$8M	$12M	—	$3M
Low	$735,575	$980,075	$1M	$1M	$8M	$12M	—	$3M
High	$735,575	$980,075	$1M	$1M	$8M	$12M	—	$3M
EBITDA Avg	—	—	—	—	—	—	—	—
Low	—	—	—	—	—	—	—	—
High	—	—	—	—	—	—	—	—
EBIT Avg	—	—	—	—	—	—	—	—
Low	—	—	—	—	—	—	—	—
High	—	—	—	—	—	—	—	—
Net Income Avg	$-109M	$-100M	$-99M	$-98M	$-97M	$-95M	$-123M	$-121M
Low	$-127M	$-119M	$-99M	$-98M	$-97M	$-95M	$-123M	$-121M
High	$-89M	$-83M	$-99M	$-98M	$-97M	$-95M	$-123M	$-121M
EPS Avg	$-0.72	$-0.67	$-0.66	$-0.65	$-0.65	$-0.63	$-0.81	$-0.80
Low	$-0.85	$-0.79	$-0.66	$-0.65	$-0.65	$-0.63	$-0.81	$-0.80
High	$-0.59	$-0.55	$-0.66	$-0.65	$-0.65	$-0.63	$-0.81	$-0.80
Analysts (Rev / EPS)	1 / 8	1 / 3	1 / 1	1 / 1	1 / 1	1 / 1	— / 2	1 / 2

Earnings Surprises

Recent Analyst Actions

Aug 12, 2026Morgan Stanley

Biohaven price target raised to $19 from $18 at Morgan Stanley

Target:$19.00

+31.1%from $14.49

Jun 29, 2026Needham

BofA Securities Downgrades Biohaven Pharma (BHVN) to Underperform

Target:$11.00

-30.5%from $15.83

May 13, 2026Morgan Stanley

Biohaven price target lowered to $18 from $21 at Morgan Stanley

Target:$18.00

+101.6%from $8.93

Mar 4, 2026H.C. Wainwright

Biohaven Pharma (BHVN) PT Lowered to $10 at H.C. Wainwright

Target:$10.00

-3.8%from $10.39

Mar 3, 2026Leerink Partners

Leerink Partners Reiterates Outperform Rating on Biohaven Pharma (BHVN), lowers EPS estimates

Target:$15.00

+40.6%from $10.67

Feb 5, 2026Goldman Sachs

Biohaven initiated with a Buy at Goldman Sachs

Target:$23.00

+113.8%from $10.76

Jan 21, 2026RBC Capital

Biohaven upgraded to Outperform from Sector Perform at RBC Capital

Target:$22.00

+73.5%from $12.68

Dec 3, 2025H.C. Wainwright

Biohaven downgraded to Neutral from Buy at H.C. Wainwright

Target:$11.00

+24.6%from $8.83

Nov 26, 2025UBS

Biohaven downgraded to Neutral from Buy at UBS

Target:$11.00

+19.0%from $9.24

Nov 18, 2025Morgan Stanley

Biohaven price target lowered to $26 from $54 at Morgan Stanley

Target:$26.00

+175.1%from $9.45

Nov 5, 2025Robert W. Baird

Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $42 at Baird

Target:$42.00

+201.1%from $13.95

Mar 20, 2025Deutsche Bank

Immunovant data positive for Biohaven, says Deutsche Bank

Target:$60.00

+112.9%from $28.18

Mar 4, 2025Bernstein

Biohaven price target lowered to $57 from $73 at Bernstein

Target:$57.00

+81.7%from $31.37

Dec 4, 2024RBC Capital

Biohaven Pharmaceutical Holding (BHVN) PT Raised to $61 at RBC Capital

Target:$61.00

+31.0%from $46.58

Oct 15, 2024Bank of America Securities

BofA Securities Reiterates Buy Rating on Biohaven Pharmaceutical Holding (BHVN)

Target:$65.00

+23.2%from $52.77

Sep 24, 2024Leerink Partners

Biohaven Pharmaceutical Holding (BHVN) PT Raised to $60 at Leerink Partners

Target:$60.00

+35.7%from $44.22

Sep 24, 2024H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Biohaven Pharmaceutical Holding (BHVN)

Target:$59.00

+28.4%from $45.94

Sep 24, 2024Bank of America Securities

Biohaven Pharmaceutical Holding (BHVN) PT Raised to $62 at BofA Securities

Target:$62.00

+35.0%from $45.94

Sep 24, 2024RBC Capital

Biohaven Pharmaceutical Holding (BHVN) PT Raised to $68 at RBC Capital

Target:$68.00

+48.0%from $45.94

Sep 23, 2024Robert W. Baird

Biohaven Pharmaceutical Holding (BHVN) PT Raised to $60 at Baird

Target:$60.00

+28.9%from $46.56

Sep 23, 2024BTIG

BTIG Reiterates Buy Rating on Biohaven Pharmaceutical Holding (BHVN), PT $59

Target:$59.00

+26.7%from $46.56

Sep 16, 2024Jefferies

Biohaven initiated with a Buy at Jefferies

Target:$57.00

+49.7%from $38.08

Sep 4, 2024Tudor Pickering

Biohaven initiated with an Outperform at Bernstein

Target:$55.00

+44.1%from $38.17

Jul 24, 2024Morgan Stanley

Biohaven initiated with an Overweight at Morgan Stanley

Target:$58.00

+53.4%from $37.81

May 29, 2024Robert W. Baird

Biohaven selloff following degrader data 'overdone,' says Baird

Target:$58.00

+91.4%from $30.31

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance